Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03649438 | 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma | no longer available | — | — | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04507919 | Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY |
| 0 |
| Nov 12, 2024 |
| clinicaltrials |
| NCT04814732 | Expanded Access Program of Surufatinib | no longer available | — | — | HutchmedINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT01838187 | Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma | no longer available | — | — | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT02431715 | 18F-FDOPA PET in Neuroendocrine Tumours | no longer available | — | — | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02174679 | 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT03503890 | Expanded Access to Rovalpituzumab Tesirine | no longer available | — | — | AbbVieINDUSTRY | 0 | Sep 10, 2019 | clinicaltrials |
| NCT01980732 | 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors | no longer available | — | — | Andrei IagaruOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02375464 | Gallium-68 DOTATOC for Management of Neuroendocrine Tumors | no longer available | — | — | Northwell HealthOTHER | 0 | Nov 8, 2016 | clinicaltrials |
| NCT02358018 | 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial | no longer available | — | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 2, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Dec 11, 2024source: clinicaltrials